Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 12/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402581 | 0.88 | ANO1 (0.60) | ANO1ALDH1A1P2RX4SMN1; SMN2RAB9A | |
| SCHEMBL30285772 | 0.86 | ANO1 (0.60) | ANO1ALDH1A1P2RX4SMN1; SMN2NPC1 | |
| SCHEMBL26186467 | 0.86 | ANO1 (0.60) | ANO1ALDH1A1P2RX4SMN1; SMN2NPC1 | |
| SCHEMBL29029228 | 0.83 | ANO1 (0.57) | ANO1ALDH1A1P2RX4SMN1; SMN2 | |
| SCHEMBL24173293 | 0.81 | SMN1; SMN2 (0.67) | ANO1ALDH1A1P2RX4SMN1; SMN2NPC1 | |
| SCHEMBL29029227 | 0.80 | ANO1 (0.58) | ANO1ALDH1A1P2RX4SMN1; SMN2KCNJ5 | |
| SCHEMBL30368210 | 0.79 | ANO1 (0.65) | ANO1ALDH1A1P2RX4SMN1; SMN2 | |
| SCHEMBL30285369 | 0.79 | P2RX4 (0.74) | ANO1ALDH1A1P2RX4SMN1; SMN2 | |
| SCHEMBL26186470 | 0.79 | P2RX4 (0.74) | ANO1ALDH1A1P2RX4SMN1; SMN2 | |
| SCHEMBL30403121 | 0.78 | ALDH1A1 (0.50) | ANO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115989218-A | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases | 拜耳公司 | 2023-04-18 | — | — | CN | claimed |